Erlotinib and vinorelbine in advanced malignant solid tumors: A phase I study

Investigational New Drugs

Volumn 25, Issue 4, 2007, Pages 351-355

  Davies, Angela M ^a   Ho, Cheryl ^b   Hesketh, Paul J ^a   Beckett, Laurel A ^a   Lara Jr , Primo N ^a   Lau, Derick Hm ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

EGFR; Erlotinib; Phase I; Vinorelbine

Indexed keywords

ERLOTINIB; NAVELBINE;

ADVANCED CANCER; AGED; ANALYTIC METHOD; ANEMIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; INFECTION; LUNG INFECTION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; QUINAZOLINES; VINBLASTINE;

EID: 34250634014     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9045-8     Document Type: Article

References (18)

1. American Cancer Society (2006) Cancer facts and figures 2006. Available at http://www.cancer.org/docroot/PRO/content/ PRO_1_1_Cancer_Statistics_2006_Presentation.asp. Accessed on December 2006
2. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
3. Johnson D, Zhu J, Schiller J et al (1999) E1594-A randomized phase III trial in metastatic non-small cell lung cancer (NSCLC)-outcome of PS 2 patients (Pts): An eastern cooperative group trial (ECOG). (Meeting abstract). ASCO, Abstract 1779
4. Gridelli C, Perrone F, Nelli F et al (2001) Quality of life in lung cancer patients. Ann Oncol 12:S21-25
5. Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The multicenter Italian lung cancer in the elderly study (MILES) Phase III randomized trial. J Natl Cancer Inst 95:362-372
6. Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol 19:183-232
7. Genentech (2005) Tarceva® Prescribing Information. Available at http://www.gene.com/gene/products/information/oncology/tarceva/insert.jsp. Accessed on December 2006
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
9. Gatzemeier UP, Szczesna A, Kaukel A, Roubec E, Brennscheidt J, DeRosa U, Mueller F, von Pawel J (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer. ASCO, New Orleans
10. Giaccone G, Herbst RS, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22:777-784
11. Herbst RS, Giaccone G, Schiller JH et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22:785-94
12. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
13. Scagliotti G, Rossi A, Novello S et al (2004) Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 22:7081:2004
14. Kajita J, Kuwabara T, Kobayashi H et al (2000) CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 28:1121-1127
15. Lilenbaum RC, Herndon JE II, List MA et al (2005) Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 23:190-196
16. Tester WJ, Stephenson P, Langer CJ et al (2004) ECOG 1599: Randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22:7055
17. Langer COK, Ross H et al (2005) Xyotax/carboplatin vs. paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy naïve advanced non small cell lung cancer (NSCLC): the STELLAR 2 phase III study. Lung Cancer 49(2):S36
18. Lilenbaum R, Axerold R, Thomas S et al (2006) Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. ASCO Meeting Abstracts 24:7022